Second generation drug eluting stents(DES) have shown better safety and efficacy in comparison to first generation DES,because of thinner struts,nondurable polymers and coating with better anti-proliferative drugs.The...Second generation drug eluting stents(DES) have shown better safety and efficacy in comparison to first generation DES,because of thinner struts,nondurable polymers and coating with better anti-proliferative drugs.The newer DES with cobalt alloy base have demonstrated a greater trackability,deliverability,conformability,flexibility and radio-opacity.However,these thin strut stents have a downside of poor longitudinal axial strength,and therefore get easily deformed/ compressed at their end with a slight trauma during exchange of various catheters.We hereby report two cases of "longitudinal stent compression(LSC)" of everolimus-eluting stent,which happened during percutaneous coronary intervention of right coronary artery.Both the cases were successfully managed with non-compliant balloon dilatation.Various reasons for LSC and its management are discussed in the article.展开更多
Background:Studies have suggested that use of prolonged dual antiplatelet therapy (DAPT) following new generation drug-eluting stent implantation may increase costs and potential bleeding events.This study aimed to in...Background:Studies have suggested that use of prolonged dual antiplatelet therapy (DAPT) following new generation drug-eluting stent implantation may increase costs and potential bleeding events.This study aimed to investigate the association of DAPT status with clinical safety in patients undergoing everolimus-eluting stent (EES) implantation in the SEEDS study (A Registry to Evaluate Safety and Effectiveness of Everolimus Drug-eluting Stent for Coronary Revascularization) at 2-year follow-up.Methods:The SEEDS study is a prospective,multicenter study,where patients (n =1900) with small vessel,long lesion,or multi-vessel diseases underwent EES implantation.Detailed DAPT status was collected at baseline,6-month,1-and 2-year.DAPT interruption was defined as any interruption of aspirin and/or clopidogrel more than 14 days.The net adverse clinical events (NACE,a composite endpoint of all-cause death,all myocardial infarction (MI),stroke,definite/probable stent thrombosis (ST),and major bleeding (Bleeding Academic Research Consortium Ⅱ-Ⅴ)) were investigated according to the DAPT status at 2-year follow-up.Results:DAPT was used in 97.8％ of patients at 6 months,69.5％ at 12 months and 35.4％ at 2 years.It was observed that the incidence of NACE was low (8.1％) at 2 years follow-up,especially its components of all-cause death (0.9％),stroke (1.1％),and definite/probable ST (0.7％).DAPT was not an independent predictor of composite endpoint of all-cause death/MI/stroke (hazard ratio [HR]:0.693,95％confidence interval [CI]:0.096-4.980,P =0.715) and NACE (HR:1.041,95％ CI:0.145-7.454,P =0.968).Of 73 patients who had DAPT interruption,no patient had ST at 12-month,and only 1 patient experienced ST between 1-and 2-year (1.4％).There was a high frequency of major bleeding events (53/65,82.5％) occurred in patients receiving DAPT treatment.Conclusions:Prolonged DAPT use was not associated with improved clinical safety.The study emphasized that duration of DAPT needs to be shortened in Chinese patients following 展开更多
目的以随机对照试验(RCT)为依据,比较生物可吸收支架(BVS)对比依维莫司洗脱支架(EES)在冠状动脉粥样硬化性心脏病(冠心病)介入治疗中的安全性和有效性。方法计算机检索数据库PubMed、Embase、Web of Science和Cochrane Library,并追踪...目的以随机对照试验(RCT)为依据,比较生物可吸收支架(BVS)对比依维莫司洗脱支架(EES)在冠状动脉粥样硬化性心脏病(冠心病)介入治疗中的安全性和有效性。方法计算机检索数据库PubMed、Embase、Web of Science和Cochrane Library,并追踪获取文献,查询时间从2008年1月至2017年9月,根据改良Jadad量表评价文献质量并提取资料,运用Review Manager 5.3软件进行Meta分析。结果通过检索共纳入7项对比BVS及EES的RCT,随访时间从9个月～3年,共5546例患者,其中BVS组3241例、EES组2305例。Meta分析结果显示,应用BVS的患者发生心肌梗死(OR=1.55,95%CI:1.22～1.96,P=0.0003)、靶血管心肌梗死(OR=1.73,95%CI:1.32～2.27,P<0.0001)、支架内血栓(OR=3.62,95%CI:2.12～6.18,P<0.0001)的风险高于应用EES患者,但在全因死亡(P=0.1)、心源性死亡(P=0.42)、所有血运重建(P=0.10)、靶病变血运重建(P=0.06)对比中两组差异无统计学意义。同时,在各项复合终点的对比中,BVS组的主要心血管不良事件(OR=1.37,P=0.0003)、面向患者的复合终点(OR=1.21,P=0.005)、面向装置的复合终点(OR=1.41,P=0.002)、靶病变失败(OR=1.44,P<0.0001)的发生率均高于EES组。结论在目前的冠心病介入治疗随访中,BVS的安全性和有效性无论是短期还是长期均不优于EES。临床应用BVS应当更加谨慎,在新一代BVS投入应用之前,现行的治疗方案仍需大量的、更长时间的随访来验证。展开更多
文摘Second generation drug eluting stents(DES) have shown better safety and efficacy in comparison to first generation DES,because of thinner struts,nondurable polymers and coating with better anti-proliferative drugs.The newer DES with cobalt alloy base have demonstrated a greater trackability,deliverability,conformability,flexibility and radio-opacity.However,these thin strut stents have a downside of poor longitudinal axial strength,and therefore get easily deformed/ compressed at their end with a slight trauma during exchange of various catheters.We hereby report two cases of "longitudinal stent compression(LSC)" of everolimus-eluting stent,which happened during percutaneous coronary intervention of right coronary artery.Both the cases were successfully managed with non-compliant balloon dilatation.Various reasons for LSC and its management are discussed in the article.
文摘Background:Studies have suggested that use of prolonged dual antiplatelet therapy (DAPT) following new generation drug-eluting stent implantation may increase costs and potential bleeding events.This study aimed to investigate the association of DAPT status with clinical safety in patients undergoing everolimus-eluting stent (EES) implantation in the SEEDS study (A Registry to Evaluate Safety and Effectiveness of Everolimus Drug-eluting Stent for Coronary Revascularization) at 2-year follow-up.Methods:The SEEDS study is a prospective,multicenter study,where patients (n =1900) with small vessel,long lesion,or multi-vessel diseases underwent EES implantation.Detailed DAPT status was collected at baseline,6-month,1-and 2-year.DAPT interruption was defined as any interruption of aspirin and/or clopidogrel more than 14 days.The net adverse clinical events (NACE,a composite endpoint of all-cause death,all myocardial infarction (MI),stroke,definite/probable stent thrombosis (ST),and major bleeding (Bleeding Academic Research Consortium Ⅱ-Ⅴ)) were investigated according to the DAPT status at 2-year follow-up.Results:DAPT was used in 97.8％ of patients at 6 months,69.5％ at 12 months and 35.4％ at 2 years.It was observed that the incidence of NACE was low (8.1％) at 2 years follow-up,especially its components of all-cause death (0.9％),stroke (1.1％),and definite/probable ST (0.7％).DAPT was not an independent predictor of composite endpoint of all-cause death/MI/stroke (hazard ratio [HR]:0.693,95％confidence interval [CI]:0.096-4.980,P =0.715) and NACE (HR:1.041,95％ CI:0.145-7.454,P =0.968).Of 73 patients who had DAPT interruption,no patient had ST at 12-month,and only 1 patient experienced ST between 1-and 2-year (1.4％).There was a high frequency of major bleeding events (53/65,82.5％) occurred in patients receiving DAPT treatment.Conclusions:Prolonged DAPT use was not associated with improved clinical safety.The study emphasized that duration of DAPT needs to be shortened in Chinese patients following
